# VASTHERA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vasthera

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.vasthera.com
- Total disclosed funding: $20M
- Latest round: Series B (Mar 2, 2022)
- Investors on record: 9

## About

Based in Seoul, South Korea, and founded in 2018 by its CEO, SangWon Kang, and COO, YongSoon Ahn, VASTHERA operates as a biotechnology company that specializes in synthetic therapeutics targeting vascular hyperplasia. In November 2020, VASTHERA raised KRW 18 billion in series B funding from returning investors ID Ventures, Medytox Venture Investment, and SJ Investment Partners, and new investors Daesung Private Equity, Holistic Growth Initiative, Medici Investment, and UTC Investment. As of March 2022, the company has a team of four people.

VASTHERA offers a platform technology for the peroxide-based redox signaling network. The company develops MOA drugs targeting arterial diseases including pulmonary arterial hypertension, a form of pulmonary hypertension, in-stent restenosis, angina, and cardiac infarction, which occur when blood flow decreases or stops to a part of the heart due to the rupture of coronary arterial vessels, causing damage to the heart muscle, atherosclerosis, a disease in which the inside of an artery narrows due to the build-up of plaque, and heart failure, when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. 

VASTHERA plans to use the series B funding for the clinical trials of new drug candidates for pulmonary arterial hypertension and preclinical trials of research on triple-negative breast cancer.

## Funding rounds

- Series B, Mar 2, 2022, $15M — Shinhan Venture Investment, Partners Investment, Daesung Private Equity, ID Ventures, UTC Investment, SJ Investment Partners, Medici Investment, Holistic Growth Initiative, Medytox Venture Investment
- Series A, Nov 12, 2020, $5M — ID Ventures, SJ Investment Partners, Medytox Venture Investment

## Investors

- ID Ventures (https://capitalatlas.ai/funds/id-ventures) — Series A, Series B
- SJ Investment Partners (https://capitalatlas.ai/funds/sj-investment-partners) — Series A, Series B
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Series A, Series B
- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series B
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series B
- Daesung Private Equity (https://capitalatlas.ai/funds/daesung-private-equity) — Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series B
- Medici Investment (https://capitalatlas.ai/funds/medici-investment) — Series B
- Holistic Growth Initiative (https://capitalatlas.ai/funds/holistic-growth-initiative) — Series B